4.7 Article

Gut microbiota combined with metabolomics reveal the mechanism of curcumol on liver fibrosis in mice

期刊

BIOMEDICINE & PHARMACOTHERAPY
卷 152, 期 -, 页码 -

出版社

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2022.113204

关键词

Hepatic fibrosis; Intestinal microbiota; Metabolomics

资金

  1. National Natural Science Foundation of China [81960751, 81960761, 81660705]
  2. Guangxi Natural Science Foundation Youth Project [2020GXNSFBA297094]
  3. Guangxi Young and Middle-aged Teachers' Research Ability Improvement Project [2020KY59009, 2022KY1667]
  4. Guangxi Zhuangyao Pharmaceutical Key Laboratory [GXZYZZ2019-1, GXZYZZ2020-07]
  5. Guangxi University of Traditional Chinese Medicine School-level Project Youth Fund [2020QN006]

向作者/读者索取更多资源

This study investigated the effects of curcumol on liver fibrosis in mice through analysis of gut microbiota and serum metabolomics. The results revealed the relationship between gut microbiota and metabolites in the process of liver fibrosis. Curcumol was found to improve pathological changes in liver tissue and inhibit liver inflammation. Furthermore, it was found to alter the abundances of certain gut bacteria and regulate arachidonic acid metabolism, suggesting its potential antihepatic fibrosis effect.
Objective: Liver fibrosis is a reversible pathological process, and its prevention and treatment hold great significance for patients with chronic liver disease. This study combined 16S rRNA analysis of gut microbiota and serum metabolomics to explore the mechanism of curcumol's effect on liver fibrosis in mice. The results clarified the relationship between the gut microbiota and metabolites in the process of liver fibrosis. Materials and methods: In this study, we randomly divided mice into a control group, a model group, and a curcumol treatment group to analyze the pathological changes in the liver tissue as well as the activities of the toll-like receptor 4 (TLR4)/nuclear factory kappa B (NF-kappa B) signaling pathway and inflammatory factors, such as tumor necrosis factor (TNF), interleukin 6 (IL-6), and IL-8. The gut microbiota were analyzed by 16 S rRNA sequencing, and serum metabolites were examined by liquid chromatography-mass spectrometry (LC-MS) metabolomic analysis. Results: Molecular biological testing found that curcumol could significantly improve the pathological changes of the liver tissue and inhibit the occurrence of liver inflammation. Intestinal flora testing found that curcumol could significantly change the abundances of Veillonellaceae, Prerotella_oulorum, and Alistipes_finegoldii. Metabolomics analysis found that curcumol's antihepatic fibrosis effect may be related to its regulation of arachidonic acid metabolism. Correlation analysis suggested that curcumol regulated the abundances of Bacteroidota and Bacteroides and participated in the metabolism of Prostaglandin B2. Conclusions: When liver fibrosis occurs, the intestinal flora and metabolic network are altered. The effect of curcumol on liver fibrosis may be related to its regulation of intestinal flora and the resulting interference with metabolic pathways, thereby reducing liver inflammation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据